{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:15:05Z","timestamp":1772151305846,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,2]]},"DOI":"10.7759\/cureus.95944","type":"journal-article","created":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:06:50Z","timestamp":1762096010000},"source":"Crossref","is-referenced-by-count":1,"title":["Chylous Ascites, a Rare Adverse Reaction to Selpercatinib"],"prefix":"10.7759","author":[{"given":"Adriana","family":"Dias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joao  O","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Madama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC","volume":"389","author":"Zhou C","year":"2023","unstructured":"Zhou C, Solomon B, Loong HH, et al.. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. N Engl J Med. 2023, 389:1839-50. 10.1056\/NEJMoa2309457","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon A","year":"2020","unstructured":"Drilon A, Oxnard GR, Tan DS, et al.. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2020, 383:813-24. 10.1056\/NEJMoa2005653","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1090757","article-title":"A comprehensive overview of the relationship between RET gene and tumor occurrence","volume":"13","author":"Zhao L","year":"2023","unstructured":"Zhao L, Wang N, Zhang D, Jia Y, Kong F. A comprehensive overview of the relationship between RET gene and tumor occurrence. Front Oncol. 2023, 13:1090757. 10.3389\/fonc.2023.1090757","journal-title":"Front Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00935-5","article-title":"Selpercatinib: a review in advanced RET fusion-positive NSCLC","volume":"18","author":"Nie T","year":"2023","unstructured":"Nie T, Syed YY. Selpercatinib: a review in advanced RET fusion-positive NSCLC. Target Oncol. 2023, 18:169-76. 10.1007\/s11523-022-00935-5","journal-title":"Target Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.06.008","article-title":"Brief report: chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy","volume":"17","author":"Kalchiem-Dekel O","year":"2022","unstructured":"Kalchiem-Dekel O, Falcon CJ, Bestvina CM, et al.. Brief report: chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy. J Thorac Oncol. 2022, 17:1130-6. 10.1016\/j.jtho.2022.06.008","journal-title":"J Thorac Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-47. 10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2017.00035","article-title":"Chylous ascites: a review of pathogenesis, diagnosis and treatment","volume":"6","author":"Bhardwaj R","year":"2018","unstructured":"Bhardwaj R, Vaziri H, Gautam A, Ballesteros E, Karimeddini D, Wu GY. Chylous ascites: a review of pathogenesis, diagnosis and treatment. J Clin Transl Hepatol. 2018, 6:105-13. 10.14218\/JCTH.2017.00035","journal-title":"J Clin Transl Hepatol"},{"key":"ref8","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0. (2017). Accessed. May 1, 2025: https:\/\/www.ctc.ucl.ac.uk\/TrialDocuments\/Uploaded\/Common%20Terminology%20Criteria%20for%20Adverse%20Events%20(CTCAE)%...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12275","article-title":"RET fusion gene: translation to personalized lung cancer therapy","volume":"104","author":"Kohno T","year":"2013","unstructured":"Kohno T, Tsuta K, Tsuchihara K, Nakaoku T, Yoh K, Goto K. RET fusion gene: translation to personalized lung cancer therapy. Cancer Sci. 2013, 104:1396-400. 10.1111\/cas.12275","journal-title":"Cancer Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/240473","article-title":"Chylous ascites: evaluation and management","volume":"2014","author":"Al-Busafi SA","year":"2014","unstructured":"Al-Busafi SA, Ghali P, Desch\u00eanes M, Wong P. Chylous ascites: evaluation and management. ISRN Hepatol. 2014, 2014:240473. 10.1155\/2014\/240473","journal-title":"ISRN Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.08.006","article-title":"Selpercatinib and pralsetinib induced chylous ascites in RET-rearranged lung adenocarcinoma: a case series","volume":"24","author":"Fricke J","year":"2023","unstructured":"Fricke J, Wang J, Gallego N, et al.. Selpercatinib and pralsetinib induced chylous ascites in RET-rearranged lung adenocarcinoma: a case series. Clin Lung Cancer. 2023, 24:666-71. 10.1016\/j.cllc.2023.08.006","journal-title":"Clin Lung Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/404314-chylous-ascites-a-rare-adverse-reaction-to-selpercatinib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:06:53Z","timestamp":1762096013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/404314-chylous-ascites-a-rare-adverse-reaction-to-selpercatinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,2]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.95944","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,2]]}}}